Polymorphisms in cytochrome P450 enzymes, such as CYP2C9 and CYP2D6, may not only affect drug clearance but may affect patient's susceptibility to drug inhibition interactions. The long term goal of this research is to understand the role of amino acid substitution due to polymorphisms in P450 enzymes in the relative susceptibility to drug-drug interactions. The metabolism of several clinically relevant drugs is greatly diminished in subjects with CYP2C9 and CYP2D6 polymorphisms, necessitating dosage adjustments. Since amino acid changes resulting from polymorphisms can affect substrate binding and turnover, inhibitor binding and effect can also be altered. Because substrates and inhibitors may bind within a P450 active site in different orientations, the degree and direction of change in inhibition is likely to be both inhibitor and genotype dependent. The proposed experiments will study common variants of CYP2C9 and CYP2D6 with known inhibitors of these enzymes and assess the degree and type of inhibition observed. T1 NMR experiments will be conducted to determine the distances and relative orientation of substrate and inhibitor from heme iron for incorporation with kinetic data into computer models predictive of drug inhibition potential based on the polymorphic form of the enzyme. Finally, differences in inhibition due to genotype will be tested in vivo with a human clinical study of drug inhibition in patients of two different CYP2C9 genotypes. Taken together, these studies will permit a better understanding of drug inhibition potential in different P450 genotypes and serve as a foundation for increasing our understanding of interindividual differences in susceptibility to drug interactions ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
1R01GM069753-01A1
Application #
6822684
Study Section
Xenobiotic and Nutrient Disposition and Action Study Section (XNDA)
Program Officer
Okita, Richard T
Project Start
2004-08-01
Project End
2008-07-31
Budget Start
2004-08-01
Budget End
2005-07-31
Support Year
1
Fiscal Year
2004
Total Cost
$240,692
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Flora, Darcy R; Tracy, Timothy S (2012) Development of an in vitro system with human liver microsomes for phenotyping of CYP2C9 genetic polymorphisms with a mechanism-based inactivator. Drug Metab Dispos 40:836-42
Subramanian, Murali; Agrawal, Vishal; Sandee, Duanpen et al. (2012) Effect of P450 oxidoreductase variants on the metabolism of model substrates mediated by CYP2C9.1, CYP2C9.2, and CYP2C9.3. Pharmacogenet Genomics 22:590-7
Sandee, Duanpen; Morrissey, Kari; Agrawal, Vishal et al. (2010) Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro. Pharmacogenet Genomics 20:677-86
Hutzler, J Matthew; Balogh, Larissa M; Zientek, Michael et al. (2009) Mechanism-based inactivation of cytochrome P450 2C9 by tienilic acid and (+/-)-suprofen: a comparison of kinetics and probe substrate selection. Drug Metab Dispos 37:59-65
Hummel, Matthew A; Gannett, Peter M; Aguilar, Jarrett et al. (2008) Substrate proton to heme distances in CYP2C9 allelic variants and alterations by the heterotropic activator, dapsone. Arch Biochem Biophys 475:175-83
Kramer, Melissa A; Tracy, Timothy S (2008) Studying cytochrome P450 kinetics in drug metabolism. Expert Opin Drug Metab Toxicol 4:591-603
Kumar, Vikas; Brundage, Richard C; Oetting, William S et al. (2008) Differential genotype dependent inhibition of CYP2C9 in humans. Drug Metab Dispos 36:1242-8
Wei, Lian; Locuson, Charles W; Tracy, Timothy S (2007) Polymorphic variants of CYP2C9: mechanisms involved in reduced catalytic activity. Mol Pharmacol 72:1280-8
Kumar, Vikas; Wahlstrom, Jan L; Rock, Dan A et al. (2006) CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles. Drug Metab Dispos 34:1966-75
Kumar, Vikas; Locuson, Chuck W; Sham, Yuk Y et al. (2006) Amiodarone analog-dependent effects on CYP2C9-mediated metabolism and kinetic profiles. Drug Metab Dispos 34:1688-96

Showing the most recent 10 out of 12 publications